Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Leqembi (lecanemab-irmb ... You may qualify for a savings program called Eisai Patient Support. The buildup of a protein called beta-amyloid is one of the changes in the brain seen in people ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Healthy returns: Japan’s assault on old-age di ...

Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly ...

Algernon to Acquire NoBrainer - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology ...

1 Day ESAIY 6.12% DJIA 0.28% S&P 500 0.40% Health Care/Life Sciences 0.58% ...